Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study.
Troya J, Dueñas C, Irazola I, de Los Santos I, de la Fuente S, Gil D, Hernández C, Galindo MJ, Gómez J, Delgado E, Moreno-García E, Pousada G, Aldámiz T, Iribarren JA, Guerra JM, Morán MÁ, Galera C, De La Fuente J, Peláez A, Cervero M, Garcinuño M, Montero M, Ceballos F, Buzón L; on behalf of the DORIPEX Study Group. Troya J, et al. Among authors: de la fuente j, de la fuente s, de los santos i. Medicine (Baltimore). 2022 Jun 17;101(24):e29252. doi: 10.1097/MD.0000000000029252. Medicine (Baltimore). 2022. PMID: 35713430 Free PMC article.
Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
Soriano V, Miralles C, Berdún MA, Losada E, Aguirrebengoa K, Ocampo A, Arazo P, Cervantes M, de los Santos I, San Joaquín I, Echeverria S, Galindo MJ, Asensi V, Barreiro P, Sola J, Hernandez-Burruezo JJ, Guardiola J, Blanco F, Martin-Carbonero L, García-Samaniego J, Nuñez M; PRESCO Study Group. Soriano V, et al. Among authors: de los santos i. Antivir Ther. 2007;12(4):469-76. Antivir Ther. 2007. PMID: 17668555 Clinical Trial.
Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial.
Núñez M, Miralles C, Berdún MA, Losada E, Aguirrebengoa K, Ocampo A, Arazo P, Cervantes M, de Los Santos I, San Joaquín I, Echeverría S, Galindo MJ, Asensi V, Barreiro P, Sola J, Hernandez-Burruezo JJ, Guardiola JM, Romero M, García-Samaniego J, Soriano V; PRESCO Study Group. Núñez M, et al. Among authors: de los santos i. AIDS Res Hum Retroviruses. 2007 Aug;23(8):972-82. doi: 10.1089/aid.2007.0011. AIDS Res Hum Retroviruses. 2007. PMID: 17725413 Clinical Trial.
Decrease in serial prevalence of coinfection with hepatitis C virus among HIV-infected patients in Spain, 1997-2006.
Pérez Cachafeiro S, Del Amo J, Iribarren JA, Salavert Lleti M, Gutiérrez F, Moreno A, Labarga P, Pineda JA, Vidal F, Berenguer J, Moreno S; Cohorts of the Spanish AIDS Research Network (CoRIS and CoRIS-MD). Pérez Cachafeiro S, et al. Clin Infect Dis. 2009 May 15;48(10):1467-70. doi: 10.1086/598333. Clin Infect Dis. 2009. PMID: 19368502
Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C.
Macías J, Neukam K, Portilla J, Iribarren JA, de Los Santos I, Rivero A, Márquez M, Delgado M, Téllez F, Merino D, Giner L, von Wichmann MA, Pineda JA; HEPRAL study team. Macías J, et al. Among authors: de los santos i. J Antimicrob Chemother. 2011 Jun;66(6):1346-50. doi: 10.1093/jac/dkr083. Epub 2011 Mar 10. J Antimicrob Chemother. 2011. PMID: 21398295
Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis.
Pineda JA, Neukam K, Mallolas J, López-Cortés LF, Cartón JA, Domingo P, Moreno S, Iribarren JA, Clotet B, Crespo M, de Los Santos I, Ortega E, Knobel H, Jiménez-Expósito MJ, Macías J. Pineda JA, et al. Among authors: de los santos i. J Infect. 2012 Feb;64(2):204-11. doi: 10.1016/j.jinf.2011.10.016. Epub 2011 Nov 25. J Infect. 2012. PMID: 22138553
Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patients.
Macías J, Neukam K, Mallolas J, López-Cortés LF, Cartón JA, Domingo P, Moreno S, Iribarren JA, Clotet B, Crespo M, de Los Santos I, Ortega E, Knobel H, Jiménez-Expósito MJ, Pineda JA; COINS Study Team. Macías J, et al. Among authors: de los santos i. HIV Clin Trials. 2012 Mar-Apr;13(2):61-9. doi: 10.1310/hct1302-61. HIV Clin Trials. 2012. PMID: 22510353
110 results